Boston Scientific, Guidant to pay $30M settlement

The Justice Department says Boston Scientific Corp. and its Guidant subsidiaries will pay $30 million to settle allegations that Guidant knowingly sold defective heart devices that health care facilities implanted in Medicare patients from 2002 to 2005.

Boston Scientific is headquartered in Natick, Mass., and acquired Guidant in 2006.

The Justice Department says that while Guidant took corrective action to fix the defects, the company continued selling its remaining stock of defective versions of the devices. In addition, the government alleged that as Guidant learned about the cause of the defect, it took steps to hide the problem from patients, doctors and the Food and Drug Administration, which regulates medical devices.

The devices are used in patients at risk of cardiac arrest due to an irregular heartbeat.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA proposes new rules for heart defibrillators

Mar 22, 2013

(AP)—The Food and Drug Administration will require makers of heart-zapping defibrillators to submit more data on their safety and effectiveness following years of recalls of the emergency devices.

US approves less-invasive heart defibrillator

Sep 29, 2012

(AP)—The U.S. Food and Drug Administration says it has approved a first-of-a-kind heart-zapping implant from Boston Scientific that that does not directly touch the heart.

FDA requires tracking codes on medical implants

Sep 20, 2013

Federal health regulators will begin tracking millions of medical devices, from pacemakers to hip replacements, using a new electronic system designed to protect patients by catching problematic implants earlier.

Recommended for you

Pay-for-performance not found to impact access to CABG

11 hours ago

(HealthDay)—For patients with acute myocardial infarction (AMI), treatment at pay-for-performance (P4P) hospitals is not associated with a change in the rate of coronary artery bypass graft (CABG) surgery, ...

A prescription for better stroke care

18 hours ago

Stroke patients are 70 per cent more likely to continue taking their stroke prevention medications one year later if they have a prescription in hand when discharged – according to researchers at St. Michael's ...

User comments